Staging systems in bipolar disorder: An International Society for Bipolar Disorders Task Force Report

Acta Psychiatrica Scandinavica

Volumn 130, Issue 5, 2014, Pages 354-363

  Kapczinski, F ^a   Magalhaes P V S ^a   Balanza Martinez V ^b   Dias, V V ^c   Frangou, S ^d   Gama, C S ^a   Gonzalez Pinto, A ^e   Grande, I ^f   Ha, K ^g   Kauer Sant'Anna, M ^a   Kunz, M ^a   Kupka, R ^h   Leboyer, M ⁱ   Lopez Jaramillo, C ^j   Post, R M ^k   Rybakowski, J K ^l   Scott, J ^d,m   Strejilevitch, S ⁿ   Tohen, M ^o   Vazquez, G ^p   Yatham, L ^q   Vieta, E ^f   Berk, M ^r,s   more..

^a HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^b UNIVERSITY OF VALENCIA   (Spain)

^c INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

^d KING'S COLLEGE LONDON   (United Kingdom)

^e UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^f UNIVERSITY OF BARCELONA   (Spain)

^g Seoul National University   (South Korea)

^h VU UNIVERSITY MEDICAL CENTER   (Netherlands)

ⁱ UNIVERSITÉ PARIS EST CRÉTEIL   (France)

^j UNIVERSIDAD DE ANTIOQUIA   (Colombia)

^k Bipolar Collaborative Network   (United States)

^l POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^m NEWCASTLE UNIVERSITY   (United Kingdom)

ⁿ FAVALORO UNIVERSITY   (Argentina)

^o UNIVERSITY OF NEW MEXICO   (United States)

^p UNIVERSITY OF PALERMO   (Argentina)

^q UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^r DEAKIN UNIVERSITY   (Australia)

^s UNIVERSITY OF MELBOURNE   (Australia)

more..

Author keywords

Bipolar disorder; Clinical aspects; Early intervention

Indexed keywords

3 NITROTYROSINE; GLUTATHIONE REDUCTASE; GLUTATHIONE TRANSFERASE; LITHIUM; NEUROTROPHIN; OLANZAPINE; BIOLOGICAL MARKER;

ANXIETY DISORDER; BIPOLAR DISORDER; COGNITION; COGNITIVE BEHAVIORAL THERAPY; COMORBIDITY; CROSS-SECTIONAL STUDY; DEPRESSION; DISEASE COURSE; DRUG DEPENDENCE; EATING DISORDER; HUMAN; MEMORY DISORDER; MENTAL DISEASE; META ANALYSIS; NEUROIMAGING; PROGNOSIS; PSYCHOEDUCATION; PSYCHOTHERAPY; REVIEW; SYSTEMATIC REVIEW; TREATMENT RESPONSE; VALIDITY; ADVISORY COMMITTEE; BLOOD; MEDICAL SOCIETY; SEVERITY OF ILLNESS INDEX;

ADVISORY COMMITTEES; BIOLOGICAL MARKERS; BIPOLAR DISORDER; DISEASE PROGRESSION; HUMANS; SEVERITY OF ILLNESS INDEX; SOCIETIES, MEDICAL;

EID: 84908687132     PISSN: 0001690X     EISSN: 16000447     Source Type: Journal    
DOI: 10.1111/acps.12305     Document Type: Review

References (85)

1. McGorry PD, Hickie IB, Yung AR, Pantelis C, Jackson HJ. Clinical staging of psychiatric disorders: a heuristic framework for choosing earlier, safer and more effective interventions. Aust N Z Psychiatry 2006;40:616-622.
2. Fava GA, Kellner R. Staging - a neglected dimension in psychiatric classification. Acta Psychiatr Scand 1993;87:225-230.
3. Cosci F, Fava GA. Staging of mental disorders: systematic review. Psychother Psychosom 2013;82:20-34.
4. McGorry PD, Killackey E, Yung A. Early intervention in psychosis: concepts, evidence and future directions. World Psychiatry 2008;7:148-156.
5. Baldessarini RJ, Tondo L, Visioli C. First-episode types in bipolar disorder: predictive associations with later illness. Acta Psychiatr Scand 2014;129:383-392.
6. Goodwin FK, Jamison KR. Manic-depressive illness: bipolar disorders and recurrent depression. New York, NY [etc.]: Oxford University Press, 2007.
7. Vieta E, Reinares M, Rosa AR. Staging bipolar disorder. Neurotox Res 2011;19:279-285.
8. Lewinsohn PM, Seeley JR, Klein DN. Bipolar disorders during adolescence. Acta Psychiatr Scand 2003;108:47-50.
9. McGorry PD, Purcell R, Hickie IB, Yung AR, Pantelis C, Jackson HJ. Clinical staging: a heuristic model for psychiatry and youth mental health. Med J Aust 2007;187:S40-S42.
10. McGorry PD. Issues for DSM-V: clinical staging: a heuristic pathway to valid nosology and safer, more effective treatment in psychiatry. Am J Psychiatry 2007;164:859-860.
11. Hickie IB, Scott J, Hermens DF et al. Clinical classification in mental health at the cross-roads: which direction next? BMC Med 2013;11:125.
12. Post RM, Altshuler LL, Frye MA et al. Complexity of pharmacologic treatment required for sustained improvement in outpatients with bipolar disorder. J Clin Psychiatry 2010;71:1176-1186.
13. Kessing LV, Mortensen PB, Bolwig TG. Clinical definitions of sensitisation in affective disorder: a case register study of prevalence and prediction. J Affect Disord 1998;47:31-39.
14. Berk M, Conus P, Lucas N et al. Setting the stage: from prodrome to treatment resistance in bipolar disorder. Bipolar Disord 2007;9:671-678.
15. Berk M, Hallam KT, McGorry PD. The potential utility of a staging model as a course specifier: a bipolar disorder perspective. J Affect Disord 2007;100:279-281.
16. Kapczinski F, Dias VV, Kauer-Sant'Anna M et al. Clinical implications of a staging model for bipolar disorders. Expert Rev Neurother 2009;9:957-966.
17. Duffy A, Alda M, Hajek T, Sherry SB, Grof P. Early stages in the development of bipolar disorder. J Affect Disord 2010;121:127-135.
18. Scott J, Leboyer M, Hickie I et al. Clinical staging in psychiatry: a cross-cutting model of diagnosis with heuristic and practical value. Br J Psychiatry 2013;202:243-245.
19. Post RM. Mechanisms of illness progression in the recurrent affective disorders. Neurotox Res 2010;18:256-271.
20. Post RM, Fleming J, Kapczinski F. Neurobiological correlates of illness progression in the recurrent affective disorders. J Psychiatr Res 2012;46:561-573.
21. Reinares M, Papachristou E, Harvey P et al. Towards a clinical staging for bipolar disorder: defining patient subtypes based on functional outcome. J Affect Disord 2013;144:65-71.
22. Scott J, Hickie IB, McGorry P. Pre-emptive psychiatric treatments: pipe dream or a realistic outcome of clinical staging models? Neuropsychiatry 2012;2:263-266.
23. Gama CS, Kunz M, Magalhaes PV, Kapczinski F. Staging and neuroprogression in bipolar disorder: a systematic review of the literature. Rev Bras Psiquiatr 2013;35:70-74.
24. Magalhaes PV, Dodd S, Nierenberg AA, Berk M. Cumulative morbidity and prognostic staging of illness in the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Aust N Z J Psychiatry 2012;46:1058-1067.
25. Sachs GS, Thase ME, Otto MW et al. Rationale, design, and methods of the systematic treatment enhancement program for bipolar disorder (STEP-BD). Biol Psychiatry 2003;53:1028-1042.
26. Rosa AR, Gonzalez-Ortega I, Gonzalez-Pinto A et al. One-year psychosocial functioning in patients in the early vs. late stage of bipolar disorder. Acta Psychiatr Scand 2012;125:335-341.
27. Post RM, Denicoff KD, Leverich GS et al. Morbidity in 258 bipolar outpatients followed for 1 year with daily prospective ratings on the NIMH life chart method. J Clin Psychiatry 2003;64:680-690; quiz 738-9.
28. Tohen M, Vieta E, Gonzalez-Pinto A, Reed C, Lin D. Baseline characteristics and outcomes in patients with first episode or multiple episodes of acute mania. J Clin Psychiatry 2010;71:255-261.
29. Scott J, Paykel E, Morriss R et al. Cognitive-behavioural therapy for severe and recurrent bipolar disorders - Randomised controlled trial. Br J Psychiatry 2006;188:313-320.
30. Reinares M, Colom F, Rosa AR et al. The impact of staging bipolar disorder on treatment outcome of family psychoeducation. J Affect Disord 2010;123:81-86.
31. Berk M, Brnabic A, Dodd S et al. Does stage of illness impact treatment response in bipolar disorder? Empirical treatment data and their implication for the staging model and early intervention. Bipolar Disord 2011;13:87-98.
32. Swann AC, Bowden CL, Calabrese JR, Dilsaver SC, Morris DD. Differential effect of number of previous episodes of affective disorder on response to lithium or divalproex in acute mania. Am J Psychiatry 1999;156:1264-1266.
33. Ketter TA, Houston JP, Adams DH et al. Differential efficacy of olanzapine and lithium in preventing manic or mixed recurrence in patients with bipolar I disorder based on number of previous manic or mixed episodes. J Clin Psychiatry 2006;67:95-101.
34. Gelenberg AJ, Kane JM, Keller MB et al. Comparison of standard and low serum levels of lithium for maintenance treatment of bipolar disorder. N Engl J Med 1989;321:1489-1493.
35. Sachs GS, Nierenberg AA, Calabrese JR et al. Effectiveness of adjunctive antidepressant treatment for bipolar depression. N Eng J Med 2007;356:1711-1722.
36. Ghaemi SN, Ostacher MM, El-Mallakh RS et al. Antidepressant discontinuation in bipolar depression: a Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) randomized clinical trial of long-term effectiveness and safety. J Clin Psychiatry 2010;71:372-380.
37. Hamilton BA, Naismith SL, Scott EM, Purcell S, Hickie IB. Disability is already pronounced in young people with early stages of affective disorders: data from an early intervention service. J Affect Disord 2011;131:84-91.
38. Azorin JM, Kaladjian A, Adida M, Fakra E, Hantouche E, Lancrenon S. Correlates of first-episode polarity in a French cohort of 1089 bipolar I disorder patients: role of temperaments and triggering events. J Affect Disord 2011;129:39-46.
39. Martinez-Aran A, Vieta E, Reinares M et al. Cognitive function across manic or hypomanic, depressed, and euthymic states in bipolar disorder. Am J Psychiatry 2004;161:262-270.
40. Goldberg JF, Harrow M, Grossman LS. Course and outcome in bipolar affective disorder: a longitudinal follow-up study. Am J Psychiatry 1995;152:379-384.
41. Judd LL, Akiskal HS, Schettler PJ et al. Psychosocial disability in the course of bipolar I and II disorders - A prospective, comparative, longitudinal study. Arch Gen Psychiatry 2005;62:1322-1330.
42. Haro JM, Reed C, Gonzalez-Pinto A, Novick D, Bertsch J, Vieta E. 2-Year course of bipolar disorder type I patients in outpatient care: factors associated with remission and functional recovery. Eur Neuropsychopharmacol 2011;21:287-293.
43. Bourne C, Aydemir O, Balanza-Martinez V et al. Neuropsychological testing of cognitive impairment in euthymic bipolar disorder: an individual patient data meta-analysis. Acta Psychiatr Scand 2013;128:149-162.
44. Tabares-Seisdedos R, Balanza-Martinez V, Sanchez-Moreno J et al. Neurocognitive and clinical predictors of functional outcome in patients with schizophrenia and bipolar I disorder at one-year follow-up. J Affect Disord 2008;109:286-299.
45. Martino DJ, Igoa A, Marengo E, Scapola M, Strejilevich SA. Neurocognitive impairments and their relationship with psychosocial functioning in euthymic bipolar II disorder. J Nerv Ment Dis 2011;199:459-464.
46. Torres IJ, Defreitas CM, Defreitas VG et al. Relationship between cognitive functioning and 6-month clinical and functional outcome in patients with first manic episode bipolar I disorder. Psychol Med 2011;41:971-982.
47. Robinson LJ, Thompson JM, Gallagher P et al. A meta-analysis of cognitive deficits in euthymic patients with bipolar disorder. J Affect Disord 2006;93:105-115.
48. Martinez-Aran A, Vieta E, Torrent C et al. Functional outcome in bipolar disorder: the role of clinical and cognitive factors. Bipolar Disord 2007;9:103-113.
49. Torres IJ, Defreitas VG, Defreitas CM et al. Neurocognitive functioning in patients with bipolar I disorder recently Recovered from a first manic episode. J Clin Psychiatry 2010;71:1234-1242.
50. Vieta E, Popovic D, Rosa AR et al. The clinical implications of cognitive impairment and allostatic load in bipolar disorder. Eur Psychiatry 2013;28:21-29.
51. Lopez-Jaramillo C, Lopera-Vasquez J, Gallo A et al. Effects of recurrence on the cognitive performance of patients with bipolar I disorder: implications for relapse prevention and treatment adherence. Bipolar Disord 2010;12:557-567.
52. Hermens DF, Hodge MAR, Naismith SL, Kaur M, Scott E, Hickie IB. Neuropsychological clustering highlights cognitive differences in young people presenting with depressive symptoms. J Int Neuropsychol Soc 2011;17:267-276.
53. Torrent C, Martinez-Aran A, Daban C et al. Cognitive impairment in bipolar II disorder. Br J Psychiatry 2006;189:254-259.
54. Mur M, Portella MJ, Martinez-Aran A, Pifarre J, Vieta E. Persistent neuropsychological deficit in euthymic bipolar patients: executive function as a core deficit. J Clin Psychiatry 2007;68:1078-1086.
55. Bonnin CM, Sanchez-Moreno J, Martinez-Aran A et al. Subthreshold symptoms in bipolar disorder: impact on neurocognition, quality of life and disability. J Affect Disord 2011;136:650-659.
56. Torrent C, C Del Mar Bonnin, Martinez-Aran A et al. Efficacy of functional remediation in bipolar disorder: a multicenter randomized controlled study. Am J Psychiatry 2013;170:852-859.
57. Juster RP, McEwen BS, Lupien SJ. Allostatic load biomarkers of chronic stress and impact on health and cognition. Neurosci Biobehav Rev 2010;35:2-16.
58. Kapczinski F, Vieta E, Andreazza AC et al. Allostatic load in bipolar disorder: implications for pathophysiology and treatment. Neurosci Biobehav Rev 2008;32:675-692.
59. Magalhaes PVS, Fries GR, Kapczinski F. Peripheral markers and the pathophysiology of bipolar disorder. Rev Psiq Clin 2012;39:60-67.
60. Berk M. Neuroprogression: pathways to progressive brain changes in bipolar disorder. Int J Neuropsychopharmacol 2009;12:441-445.
61. Berk M, Kapczinski F, Andreazza AC et al. Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors. Neurosci Biobehav Rev 2011;35:804-817.
62. Magalhaes PV, Kapczinski F, Nierenberg AA et al. Illness burden and medical comorbidity in the Systematic Treatment Enhancement Program for Bipolar Disorder. Acta Psychiatr Scand 2012;125:303-308.
63. Magalhaes PV, Dean OM, Bush AI et al. Systemic illness moderates the impact of N-acetyl cysteine in bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry 2012;37:132-135.
64. Kauer-Sant'Anna M, Kapczinski F, Andreazza AC et al. Brain-derived neurotrophic factor and inflammatory markers in patients with early- vs. late-stage bipolar disorder. Int J Neuropsychopharmacol 2009;12:447-458.
65. Andreazza AC, Kapczinski F, Kauer-Sant'Anna M et al. 3-Nitrotyrosine glutathione antioxidant system in patients in the early late stages of bipolar disorder. J Psychiatry Neurosci 2009;34:263-271.
66. Kapczinski F, Dal-Pizzol F, Teixeira AL et al. Peripheral biomarkers and illness activity in bipolar disorder. J Psychiatr Res 2011;45:156-161.
67. Magalhaes PVS, Jansen K, Pinheiro RT et al. Peripheral oxidative damage in early-stage mood disorders: a nested population-based case-control study. Int J Neuropsychopharmacol 2012;15:1043-1050.
68. Post RM. Kindling and sensitization as models for affective episode recurrence, cyclicity, and tolerance phenomena. Neurosci Biobehav Rev 2007;31:858-873.
69. Post RM. Role of BDNF in bipolar and unipolar disorder: clinical and theoretical implications. J Psychiatr Res 2007;41:979-990.
70. Fernandes BS, Gama CS, Cereser KM et al. Brain-derived neurotrophic in mania, depression, and euthymia in bipolar disorders: a systematic review and meta-analysis. Bipolar Disord 2010;12:19.
71. Kapczinski F, Dal-Pizzol F, Teixeira AL et al. A systemic toxicity index developed to assess peripheral changes in mood episodes. Mol Psychiatry 2010;15:784-786.
72. Magalhaes PVS, Jansen K, Pinheiro RT et al. Systemic toxicity in early-stage mood disorders. J Psychiatr Res 2011;45:1407-1409.
73. Lin A, Reniers RL, Wood SJ. Clinical staging in severe mental disorder: evidence from neurocognition and neuroimaging. Br J Psychiatry Suppl 2013;54:11-17.
74. Vita A, de Peri L, Sacchetti E. Gray matter, white matter, brain, and intracranial volumes in first-episode bipolar disorder: a meta-analysis of magnetic resonance imaging studies. Bipolar Disord 2009;11:807-814.
75. Bora E, Fornito A, Yucel M, Pantelis C. Voxelwise meta-analysis of gray matter abnormalities in bipolar disorder. Biol Psychiatry 2010;67:1097-1105.
76. Arango C, Rapado-Castro M, Reig S et al. Progressive brain changes in children and adolescents with first-episode psychosis. Arch Gen Psychiatry 2012;69:16-26.
77. Javadapour A, Malhi GS, Ivanovski B, Chen X, Wen W, Sachdev P. Increased anterior cingulate cortex volume in bipolar I disorder. Aust N Z J Psychiatry 2007;41:910-916.
78. Lagopoulos J, Hermens DF, Naismith SL, Scott EM, Hickie IB. Frontal lobe changes occur early in the course of affective disorders in young people. BMC Psychiatry 2012;12:4.
79. Nery FG, Chen HH, Hatch JP et al. Orbitofrontal cortex gray matter volumes in bipolar disorder patients: a region-of-interest MRI study. Bipolar Disord 2009;11:145-153.
80. Lim CS, Baldessarini RJ, Vieta E, Yucel M, Bora E, Sim K. Longitudinal neuroimaging and neuropsychological changes in bipolar disorder patients: review of the evidence. Neurosci Biobehav Rev 2013;37:418-435.
81. Balanza-Martinez V, Tabares-Seisdedos R, Selva-Vera G et al. Persistent cognitive dysfunctions in bipolar I disorder and schizophrenic patients: a 3-year follow-up study. Psychother Psychosom 2005;74:113-119.
82. Miklowitz DJ, Schneck CD, Singh MK et al. Early intervention for symptomatic youth at risk for bipolar disorder: a randomized trial of family-focused therapy. J Am Acad Child Adolesc Psychiatry 2013;52:121-131.
83. MacNeil CA, Hasty M, Cotton S et al. Can a targeted psychological intervention be effective for young people following a first manic episode? Results from an 18-month pilot study. Early Interv Psychiatry 2012;6:380-388.
84. Berk M, Hallam K, Malhi GS et al. Evidence and implications for early intervention in bipolar disorder. J Ment Health 2010;19:113-126.
85. Berk M, Berk L, Udina M et al. Palliative models of care for later stages of mental disorder: maximizing recovery, maintaining hope, and building morale. Aust N Z J Psychiatry 2012;46:92-99.